---
title: "Global Oral Solid Dosage Forms (OSDF) and Pharma Excipients Market Research Report 2025(Status and Outlook)"
datePublished: Fri Nov 14 2025 04:14:40 GMT+0000 (Coordinated Universal Time)
cuid: cmhycgeam000302jx37glh9m8
slug: global-oral-solid-dosage-forms-osdf-and-pharma-excipients-market-research-report-2025status-and-outlook

---

# Global Oral Solid Dosage Forms (OSDF) and Pharma Excipients Market Research Report 2025(Status and Outlook)

<p>
</p><p><strong>MARKET INSIGHTS</strong></p><p>
</p><div><b>Download FREE Sample of this Report @ 
            <a href="https://www.24chemicalresearch.com/download-sample/255766/global-oral-solid-dosage-forms-pharma-excipients-market">
            https://www.24chemicalresearch.com/download-sample/255766/global-oral-solid-dosage-forms-pharma-excipients-market</a></b></div><br><p>Global Oral Solid Dosage Forms (OSDF) and Pharma Excipients market size was valued at USD 810.52 million in 2024. The market is projected to grow from USD 845.83 million in 2025 to USD 1.22 billion by 2032, exhibiting a CAGR of 5.1% during the forecast period.</p><p>
</p><p>Oral Solid Dosage Forms (OSDF) are pharmaceutical formulations administered through the mouth in solid form, including tablets, capsules, and powders. Pharma excipients are inactive substances that serve as carriers for active pharmaceutical ingredients, enhancing stability, bioavailability, and patient compliance. Common excipients include binders, fillers, disintegrants, lubricants, and coating materials such as glycerin, propylene glycol, and mannitol.</p><p>
</p><p>The market growth is driven by increasing demand for generic drugs, advancements in drug delivery technologies, and rising prevalence of chronic diseases requiring long-term medication. While conventional tablets dominate the market, orally disintegrating tablets (ODTs) are gaining traction due to improved patient compliance. Furthermore, stringent regulatory requirements and the growing biologics market are pushing innovation in excipient formulations to meet complex drug delivery needs.</p><p>
</p><p>
<strong>MARKET DRIVERS</strong></p><p>
</p><p style="text-align:center"><strong>Growing Pharmaceutical Industry to Propel OSDF Market Expansion</strong></p><p>
</p><p>The global pharmaceutical industry has demonstrated strong growth, with projections indicating market expansion at a 6% CAGR through 2032. This sustained growth directly correlates with increased demand for oral solid dosage forms, which account for approximately 60% of all pharmaceutical dosage forms administered worldwide. Tablets and capsules remain the preferred delivery methods due to their patient compliance advantages, cost-effectiveness, and manufacturing scalability. The market is further bolstered by rising investments in pharmaceutical manufacturing infrastructure, particularly in emerging markets where healthcare access continues to improve.</p><p>
</p><p style="text-align:center"><strong>Advancements in Excipient Technology to Enhance Drug Performance</strong></p><p>
</p><p>Modern pharmaceutical excipients have evolved beyond simple inert substances to become functional components that optimize drug delivery. Smart excipients capable of controlled release, enhanced bioavailability, and stability improvements are gaining traction. Multifunctional excipients that combine binding, disintegrating, and lubricating properties in single components are reducing formulation complexity while improving production efficiency. The excipients market has grown at a steady 5% annually, with specialty excipients expected to capture a 35% market share by 2032. This technological evolution is enabling pharmaceutical companies to address previously challenging formulation requirements for poorly soluble drugs and complex generics.</p><p>
</p><p style="text-align:center"><strong>Aging Population and Chronic Disease Prevalence to Drive Market Demand</strong></p><p>
</p><p>Demographic shifts toward an older population and increasing chronic disease burdens are creating sustained demand for oral solid dosage medications. The global population aged 60+ is projected to reach 2.1 billion by 2032, with this demographic consuming medications at 3-5 times the rate of younger populations. Concurrently, chronic conditions requiring long-term medication regimens - including diabetes, cardiovascular diseases, and neurological disorders - are expanding globally. These factors collectively ensure stable market growth for oral solid dosage forms, particularly in modified-release formulations that enhance therapeutic outcomes for chronic conditions.</p><p>

</p><p><strong>â¤ Emerging markets in Asia Pacific are demonstrating particular growth, with pharmaceutical spending expected to increase by 8-10% annually through 2032, significantly outpacing developed markets.</strong></p><p>
<strong>MARKET RESTRAINTS</strong></p><p>
</p><p style="text-align:center"><strong>Stringent Regulatory Requirements to Constrain Market Development</strong></p><p>
</p><p>The pharmaceutical excipient market faces significant regulatory complexities across different regions, with approval processes often extending 12-18 months for novel excipients. Regulatory agencies have increased scrutiny following quality issues with certain pharmaceutical ingredients, leading to more rigorous documentation requirements. This regulatory burden is particularly challenging for smaller manufacturers with limited compliance resources. While essential for patient safety, these stringent requirements create barriers to market entry and innovation, potentially slowing the introduction of advanced excipient technologies.</p><p>
</p><p style="text-align:center"><strong>Genericization Pressure to Impact Profit Margins</strong></p><p>
</p><p>Patent expirations and subsequent generic competition create downward pricing pressure throughout the pharmaceutical value chain, including excipient suppliers. For commonly used excipients, manufacturers face margin compression as formulation costs become a key competitive differentiator in generic markets. This is particularly evident in developed markets where generic penetration exceeds 80% of prescriptions. While volume increases partially offset price declines, the need for cost-effective manufacturing solutions limits investment in innovative excipient development for established drug categories.</p><p>
<strong>MARKET CHALLENGES</strong></p><p>
</p><p style="text-align:center"><strong>Bioavailability Challenges with New Chemical Entities to Present Formulation Hurdles</strong></p><p>
</p><p>Approximately 40% of newly developed active pharmaceutical ingredients fall into Biopharmaceutics Classification System (BCS) Class II or IV, characterized by poor solubility and bioavailability. These pharmacologically promising compounds require advanced formulation strategies and specialized excipients to achieve therapeutic efficacy. The development of appropriate oral solid dosage forms for such compounds presents technical challenges that can delay commercial launches and increase development costs. While novel excipients can address these challenges, their regulatory approval pathways remain complex and time-intensive.</p><p>
</p><p><strong>Additional Challenges</strong></p><p>
</p><p><strong>Supply Chain Vulnerabilities</strong></p><p>
Global supply chain disruptions have highlighted dependencies on specific excipient manufacturers and geographies. Single-source suppliers for critical excipients create potential bottlenecks, with recent events demonstrating how regional disruptions can impact global pharmaceutical production.</p><p>
</p><p><strong>Talent Shortages</strong></p><p>
The specialized nature of pharmaceutical formulation development requires skilled professionals in both excipient science and regulatory affairs. The industry faces recruitment challenges as the demand for these specialists outpaces the available talent pool, particularly in emerging pharmaceutical markets.</p><p>
<strong>MARKET OPPORTUNITIES</strong></p><p>
</p><p style="text-align:center"><strong>Personalized Medicine and Orphan Drugs to Create New Excipient Demands</strong></p><p>
</p><p>The personalized medicine market is projected to grow at a 9% CAGR through 2032, driving demand for specialized excipients that enable patient-specific formulations. Similarly, orphan drug development for rare diseases often requires tailored excipient solutions to address unique pharmacokinetic challenges. These high-value, low-volume therapeutic areas present opportunities for excipient manufacturers to develop specialized product lines with higher margins compared to conventional excipients.</p><p>
</p><p style="text-align:center"><strong>Continuous Manufacturing Adoption to Revolutionize Production Economics</strong></p><p>
</p><p>The pharmaceutical industry's transition from batch to continuous manufacturing presents significant opportunities for excipient innovation. Continuous processes require excipients with highly consistent performance characteristics and real-time quality monitoring capabilities. Early adopters of continuous manufacturing report 30-50% reductions in production costs and 50-70% reductions in cycle times. As this paradigm shift accelerates, excipient manufacturers that can provide materials optimized for continuous processes will gain competitive advantage in high-value pharmaceutical partnerships.</p><p>

Global Oral Solid Dosage Forms (OSDF) and Pharma Excipients Market Analysis 2024-2032</p><p>

Market Overview
</p><p>The global oral solid dosage forms (OSDF) and pharmaceutical excipients market continues to demonstrate robust growth, driven by increasing demand for convenient and stable drug delivery systems. With the pharmaceutical industry's continued focus on precision medicine and personalized treatments, the demand for high-quality excipients that ensure drug stability and bioavailability remains strong across all regions.</p><p>

Market Size and Growth Projections
</p><p>The market size reached USD 750.77 million in 2023 and is projected to grow at a CAGR of 4.30% through 2029, reaching USD 966.53 million. This growth is primarily attributed to:</p><p>

Market Segmentation Analysis</p><p>
By Functionality
</p><p>
By Material Type
</p><p>

Regional Market Analysis
</p><p>The global OSDF and pharma excipients market shows distinct regional characteristics:</p><p>
North America
</p><p>Holds the largest market share (approximately 40%), driven by advanced pharmaceutical industry, strong regulatory framework, and high healthcare spending. The U.S. FDA's stringent quality requirements continue to drive innovation in excipient technology.</p><p>
Europe
</p><p>Accounts for approximately 30% of the global market. The presence of major pharmaceutical companies and strict EMA regulations ensure high-quality standards in excipient manufacturing and usage.</p><p>
Asia-Pacific
</p><p>Fastest growing region (CAGR ~6.5%), driven by expanding generic drug manufacturing in India, growing pharmaceutical industry in China, and increasing healthcare investment across Southeast Asia.</p><p>

Key Market Drivers

</p><p>

Industry Challenges
</p><p>

Leading Market Players
</p><p>The global OSDF and pharma excipients market features several dominant players and specialized manufacturers:</p><p>
Multinational Corporations
</p><p>
Specialized Manufacturers
</p><p>

Future Outlook and Trends
</p><p>The OSDF and pharma excipients market is expected to maintain steady growth, driven by:</p><p>

Regulatory Landscape
</p><p>The market operates under stringent regulatory frameworks that significantly influence product development and market access:</p><p>
International Standards
</p><p>
Regional Regulatory Agencies
</p><p>

Investment and Development Trends
</p><p>The industry continues to attract investment in several key areas:</p><p>
Research and Development
</p><p>Significant investments in novel excipient development to address challenges in drug delivery, particularly for biologics and complex molecules.</p><p>
Capacity Expansion
</p><p>Leading manufacturers continue to invest in production capacity to meet growing demand, particularly in Asia-Pacific regions.</p><p>
Strategic Partnerships
</p><p>Increasing collaborations between excipient manufacturers and pharmaceutical companies to develop customized solutions for specific therapeutic areas.</p><p>
Digital Transformation
</p><p>Adoption of digital technologies for quality control, supply chain management, and customer engagement.</p><p>

Conclusion
</p><p>The global OSDF and pharma excipients market demonstrates resilient growth driven by fundamental healthcare needs and pharmaceutical industry expansion. While facing challenges such as regulatory complexity and cost pressures, the market benefits from technological advancements and increasing global healthcare access. Strategic focus on quality assurance, regulatory compliance, and sustainable practices will be key success factors for industry participants through 2032.</p><p>
<strong>Key Industry Players</strong></p><p>
</p><p style="text-align:center"><strong>Companies Strive to Strengthen their Product Portfolio to Sustain Competition</strong></p><p>
</p><p>The competitive landscape of the Global Oral Solid Dosage Forms (OSDF) and Pharma Excipients Market is fragmented, featuring a mix of multinational corporations, specialty chemical manufacturers, and regional suppliers. <strong>BASF SE</strong> maintains a dominant position, leveraging its extensive portfolio of multifunctional excipients and strong technical support services across North America, Europe, and Asia-Pacific. The company's commitment to innovation, particularly in developing excipients for controlled-release formulations, solidifies its market leadership.</p><p>
</p><p><strong>DowDuPont</strong> (now operating as DuPont de Nemours, Inc. and Dow Inc. following the split) and <strong>Evonik Industries AG</strong> also command significant market shares as of 2024. Their growth is propelled by robust R&amp;D capabilities and strategic focus on high-value, specialty excipients that address complex formulation challenges, such as improving bioavailability and ensuring stability.</p><p>
</p><p>Furthermore, these established players are actively pursuing growth through geographic expansion into emerging markets and through a series of new product launches. For instance, investments in plant-based and sustainably sourced excipients are becoming a key differentiator to meet evolving regulatory and consumer demands.</p><p>
</p><p>Meanwhile, companies like <strong>Ashland Global Holdings Inc.</strong> and <strong>Roquette FrÃ¨res</strong> are enhancing their competitive standing through significant R&amp;D investments, strategic acquisitions, and partnerships. Ashland's focus on novel polymer technologies and Roquette's leadership in plant-derived excipients, such as pea starch and soluble fibers, are critical strategies to capture growth in the evolving pharmaceutical landscape.</p><p>
<strong>List of Key Companies Profiled</strong></p><p>
</p><p>BASF SE (Germany)</p><p>DuPont de Nemours, Inc. (U.S.)</p><p>Evonik Industries AG (Germany)</p><p>Ashland Global Holdings Inc. (U.S.)</p><p>Roquette FrÃ¨res (France)</p><p>Archer Daniels Midland Company (ADM) (U.S.)</p><p>Croda International Plc (U.K.)</p><p>DFE Pharma (Germany)</p><p>J.M. Huber Corporation (U.S.)</p><p>Colorcon Inc. (U.S.)</p><p>
<strong>GLOBAL ORAL SOLID DOSAGE FORMS (OSDF) AND PHARMA EXCIPIENTS MARKET TRENDS</strong></p><p>
<strong>Growing Emphasis on Patient-Centric Formulations Fuels Market Expansion</strong></p><p>
</p><p>The oral solid dosage forms (OSDF) market is undergoing a transformation as pharmaceutical companies increasingly prioritize <strong>patient adherence and convenience</strong> in drug delivery. This trend is driving innovation in tablet coatings, multi-particulate systems, and orally disintegrating tablets that improve swallowability and bioavailability. While conventional tablets still dominate with approximately 60% market share, emerging technologies like 3D-printed pills are gaining traction, enabling personalized dosing combinations. Furthermore, the global pharma excipients market is projected to grow at a <strong>CAGR of 5.8%</strong> from 2025 to 2032, supported by advances in functional excipients that enhance drug stability and release profiles.</p><p>
<strong>Other Trends</strong></p><p>
</p><p><strong>Biodegradable Excipients Development</strong></p><p>
</p><p>The increasing environmental concerns in pharmaceutical manufacturing have accelerated research into sustainable excipients. Biopolymers like chitosan and cellulose derivatives are replacing synthetic materials in coating applications, with market demand projected to increase by <strong>23% annually</strong> through 2032. This shift not only addresses regulatory pressures but also aligns with consumer preferences for eco-friendly medications. Manufacturers are simultaneously developing novel co-processed excipients that combine multiple functionalities, reducing the number of components needed in formulations while improving performance characteristics.</p><p>
<strong>Regulatory Harmonization Impact</strong></p><p>
</p><p>The International Council for Harmonisation (ICH) guidelines are reshaping global excipient standards, creating both opportunities and challenges for market players. Recent updates to Good Manufacturing Practice (GMP) requirements for excipients have led to <strong>15-20% increases</strong> in quality control investments among major suppliers. This standardization is particularly beneficial for emerging markets, where regulatory alignment facilitates cross-border trade. The harmonization efforts are also accelerating approval timelines for novel excipient combinations, with the FDA's Emerging Technology Program reporting a <strong>30% reduction</strong> in review periods for innovative OSDF technologies.</p><p>



Global Oral Solid Dosage Forms (OSDF) and Pharma Excipients Market Analysis 2024
Executive Summary
</p><p>The global oral solid dosage forms (OSDF) and pharmaceutical excipients market continues to demonstrate robust growth, driven by increasing pharmaceutical production, the rise of generic medicines, and growing demand for advanced drug delivery systems. The market reached USD 750.77 million in 2023 and is projected to reach USD 966.53 million by 2029, growing at a CAGR of 4.30% during this period.</p><p>
Market Overview
</p><p>Oral solid dosage forms remain the most preferred drug delivery method globally due to their stability, ease of administration, and cost-effectiveness. The market encompasses both the active pharmaceutical ingredients and the excipients that facilitate drug delivery, stability, and bioavailability.</p><p>
Regional Analysis</p><p>

North America
</p><p>North America represents the largest and most advanced market for OSDF and pharmaceutical excipients, accounting for approximately 38% of the global market share. The region's dominance is driven by:</p><p>The United States alone accounts for over 85% of the North American market, with Canada contributing most of the remainder. Market growth in this region is driven by increasing generic drug production, personalized medicine approaches, and quality enhancement initiatives.</p><p>

Europe
</p><p>Europe represents the second largest market for OSDF and pharma excipients, with approximately 30% global market share. The market is characterized by:</p><p>The European market shows particular strength in controlled-release formulations and pediatric formulations, where specialized excipients see strong demand.</p><p>

Asia-Pacific
</p><p>The Asia-Pacific region represents the fastest growing market for OSDF and pharma excipients, projected to grow at 6.2% CAGR through 2029. Key characteristics include:</p><p>China has become the world's largest producer of certain excipients, particularly in the starch and cellulose derivatives categories, while India leads in production of some natural gums and derivatives.</p><p>

Rest of World
</p><p>Other regions including Latin America, Middle East, and Africa collectively account for approximately 15% of the global market. These regions primarily represent demand centers rather than production hubs, though some local production exists in larger economies like Brazil and South Africa.</p><p>
Market Drivers and Trends
</p><p>The market is being primarily driven by:</p><p>
Market Challenges
</p><p>Despite strong growth, the market faces several challenges:</p><p>
Future Outlook
</p><p>The OSDF and pharma excipients market is expected to continue its steady growth through the next decade, with particular opportunities in:</p><p>The market will continue to be led by North America and Europe in terms of value, though Asia-Pacific will see the strongest growth rates and gradually increase market share.</p><p>
</p><p>This report presents a comprehensive analysis of the global and regional markets for Oral Solid Dosage Forms (OSDF) and Pharma Excipients, covering the period from 2025 to 2032. It includes detailed insights into the current market status and outlook across various regions and countries, with specific focus on:</p><p>
</p><p><strong>Sales, sales volume, and revenue forecasts</strong></p><p><strong>Detailed segmentation by type and application</strong></p><p>
</p><p>In addition, the report offers in-depth profiles of key industry players, including:</p><p>
</p><p>Company profiles</p><p>Product specifications</p><p>Production capacity and sales</p><p>Revenue, pricing, gross margins</p><p>Sales performance</p><p>
</p><p>It further examines the competitive landscape, highlighting the major vendors and identifying the critical factors expected to challenge market growth.</p><p>
</p><p>As part of this research, we surveyed Oral Solid Dosage Forms (OSDF) and Pharma Excipients companies and industry experts. The survey covered various aspects, including:</p><p>
</p><p>Revenue and demand trends</p><p>Product types and recent developments</p><p>Strategic plans and market drivers</p><p>Industry challenges, obstacles, and potential risks</p><p>
<strong>FREQUENTLY ASKED QUESTIONS:</strong></p><p>
<strong>What is the current market size of Global Oral Solid Dosage Forms (OSDF) and Pharma Excipients Market?</strong></p><p>
</p><p><strong>-&gt;</strong> Global Oral Solid Dosage Forms (OSDF) and Pharma Excipients Market was valued at <strong>USD 845.83 million in 2025</strong> and is expected to reach <strong>USD 1.22 billion by 2032</strong>.</p><p>
<strong>Which key companies operate in Global Oral Solid Dosage Forms (OSDF) and Pharma Excipients Market?</strong></p><p>
</p><p><strong>-&gt; Key players</strong> include <strong>ABITEC Corporation, AkzoNobel, Archer Daniels Midland (ADM), BASF, DowDuPont, Evonik, J.M. Huber Corporation, Cargill, and Eastman Chemical Company</strong>, among others.</p><p>
<strong>What are the key growth drivers of Global Oral Solid Dosage Forms (OSDF) and Pharma Excipients Market?</strong></p><p>
</p><p>-&gt; Key growth drivers include <strong>increasing demand for generic drugs, advancements in drug delivery technologies, and rising prevalence of chronic diseases</strong>.</p><p>
<strong>Which region dominates the market?</strong></p><p>
</p><p><strong>-&gt; Asia-Pacific</strong> is the fastest-growing region, while <strong>North America</strong> remains a dominant market.</p><p>
<strong>What are the emerging trends?</strong></p><p>
</p><p>-&gt; Emerging trends include <strong>orally disintegrating tablets (ODTs), novel excipient formulations, and improved patient compliance solutions</strong>.</p><p>
</p>

<div><b>Get the Complete Report & TOC @ 
            <a href="https://www.24chemicalresearch.com/reports/255766/global-oral-solid-dosage-forms-pharma-excipients-market">
            https://www.24chemicalresearch.com/reports/255766/global-oral-solid-dosage-forms-pharma-excipients-market</a></b></div><br>
            <b>Table of Content:</b><p>Table of Contents<br />
1 Research Methodology and Statistical Scope<br />
1.1 Market Definition and Statistical Scope of Oral Solid Dosage Forms (OSDF) and Pharma Excipients<br />
1.2 Key Market Segments<br />
1.2.1 Oral Solid Dosage Forms (OSDF) and Pharma Excipients Segment by Type<br />
1.2.2 Oral Solid Dosage Forms (OSDF) and Pharma Excipients Segment by Application<br />
1.3 Methodology & Sources of Information<br />
1.3.1 Research Methodology<br />
1.3.2 Research Process<br />
1.3.3 Market Breakdown and Data Triangulation<br />
1.3.4 Base Year<br />
1.3.5 Report Assumptions & Caveats<br />
2 Oral Solid Dosage Forms (OSDF) and Pharma Excipients Market Overview<br />
2.1 Global Market Overview<br />
2.1.1 Global Oral Solid Dosage Forms (OSDF) and Pharma Excipients Market Size (M USD) Estimates and Forecasts (2019-2030)<br />
2.1.2 Global Oral Solid Dosage Forms (OSDF) and Pharma Excipients Sales Estimates and Forecasts (2019-2030)<br />
2.2 Market Segment Executive Summary<br />
2.3 Global Market Size by Region<br />
3 Oral Solid Dosage Forms (OSDF) and Pharma Excipients Market Competitive Landscape<br />
3.1 Global Oral Solid Dosage Forms (OSDF) and Pharma Excipients Sales by Manufacturers (2019-2024)<br />
3.2 Global Oral Solid Dosage Forms (OSDF) and Pharma Excipients Revenue Market Share by Manufacturers (2019-2024)<br />
3.3 Oral Solid Dosage Forms (OSDF) and Pharma Excipients Market Share by Company Type (Tier 1, Tier 2, and Tier 3)<br />
3.4 Global Oral Solid Dosage Forms (OSDF) and Pharma Excipients Average Price by Manufacturers (2019-2024)<br />
3.5 Manufacturers Oral Solid Dosage Forms (OSDF) an</p>

<div><b>Get the Complete Report & TOC @ 
            <a href="https://www.24chemicalresearch.com/reports/255766/global-oral-solid-dosage-forms-pharma-excipients-market">
            https://www.24chemicalresearch.com/reports/255766/global-oral-solid-dosage-forms-pharma-excipients-market</a></b></div><br>

<b>CONTACT US:</b><br>
            203A, City Vista, Fountain Road, Kharadi, Pune, India - 411014<br>
            International: +1(332) 2424 294<br>
            Asia: +91 9169162030 <br><br>
            Follow Us On LinkedIn: <a href="https://www.linkedin.com/company/24chemicalresearch/">24ChemicalResearch LinkedIn</a>